Headache News and Research

Latest Headache News and Research

Acorda commences AMPYRA clinical study for post-stoke deficits

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in a proof-of-concept study exploring the use of AMPYRA(dalfampridine) Extended Release Tablets, 10 mg in treating patients who have post-stroke deficits.

13 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Researchers identify six genes that predispose to migraine without aura

Researchers studied genetic data of more than 11 000 people and found altogether six genes that predispose to migraine without aura. Four of these genes are new and two of them confirm previous findings.

11 Jun 2012

Zafgen announces new data from two Phase 1 studies of beloranib on obesity

Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new data from two Phase 1 studies of beloranib, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed significant weight loss and improvements in cardiometabolic risk markers in severely obese women.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Adolescent mental disorders have repercussions for addiction

Adolescents with mental health disorders are significantly more likely to become addicted to prescription opioid pain relievers than those without mental disorders, experts say.

8 Jun 2012

Research roundup: Savings from electronic health records?

Does Health Information Exchange Reduce Unnecessary Neuroimaging and Improve Quality of Headache Care in the Emergency Department?

8 Jun 2012

Concussion victims have unique spatial patterns of brain abnormalities that change over time

Patients vary widely in their response to concussion, but scientists haven't understood why. Now, using a new technique for analyzing data from brain imaging studies, researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that concussion victims have unique spatial patterns of brain abnormalities that change over time

8 Jun 2012

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.

7 Jun 2012

Young adults, adolescents with mental health disorders more likely to become long-term opioid users

Long-term use and abuse of opioid painkillers, such as OxyContin and Vicodin, has markedly increased in the United States in the last two decades. Of note, prescription opioids constitute 86.9 percent of prescription drug misuse among high school students. And last week in a two-day U.S. Food and Drug Administration public meeting, officials questioned the use of long-term opioids for chronic pain due to a lack of evidence for the effectiveness and concerns about the potential risk for addiction.

7 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.

2 Jun 2012

Top-line results from Genzyme’s teriflunomide Phase III trial on MS

Genzyme, a Sanofi company, announced today top-line results from the TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis) trial that assessed the efficacy and safety of once-daily, oral teriflunomide in patients with relapsing forms of multiple sclerosis.

1 Jun 2012

NYU Langone establishes unique neuromodulation center

The Department of Neurosurgery at NYU Langone Medical Center has established a unique, multidisciplinary neuromodulation center for the treatment of complex neurological conditions including movement disorders like Parkinson's disease, chronic pain and psychiatric condition such as obsessive compulsive disorder and severe depression.

31 May 2012

Acorda Therapeutics launches Ampyra Dialogues on World MS Day

Acorda Therapeutics, Inc., makers of Ampyra (dalfampridine), today announced the launch of Ampyra Dialogues, the first-ever online talk show where patients and medical experts talk about how walking problems affect people living with MS.

31 May 2012

Dehydration: how much should we drink per day?

As the northern hemisphere approaches the summer months, many of us begin to think about drinking more to prevent dehydration. But exactly how much should we be drinking a day? Does the amount vary depending on what we are drinking? And what happens if we don’t drink enough fluid?

30 May 2012

Corrected interim data from Vertex VX-809, KALYDECO combination Phase 2 study for CF

Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.

30 May 2012

EMA CHMP issues positive opinion to Eisai’s Fycompa for treatment of partial-onset seizures

Eisai announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Fycompa (perampanel) as an adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

29 May 2012

Important heat safety tips from Pennsylvania Departments of Health and Aging

With hot temperatures and high humidity expected to make an early appearance in some parts of Pennsylvania this Memorial Day weekend, the Departments of Health and Aging are urging everyone to take simple steps to prevent serious heat-related illness or even death.

28 May 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012

Headache News and Research

Latest Headache News and Research

Acorda commences AMPYRA clinical study for post-stoke deficits

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Researchers identify six genes that predispose to migraine without aura

Zafgen announces new data from two Phase 1 studies of beloranib on obesity

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Adolescent mental disorders have repercussions for addiction

Research roundup: Savings from electronic health records?

Concussion victims have unique spatial patterns of brain abnormalities that change over time

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

Young adults, adolescents with mental health disorders more likely to become long-term opioid users

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

Top-line results from Genzyme’s teriflunomide Phase III trial on MS

NYU Langone establishes unique neuromodulation center

Acorda Therapeutics launches Ampyra Dialogues on World MS Day

Dehydration: how much should we drink per day?

Corrected interim data from Vertex VX-809, KALYDECO combination Phase 2 study for CF

EMA CHMP issues positive opinion to Eisai’s Fycompa for treatment of partial-onset seizures

Important heat safety tips from Pennsylvania Departments of Health and Aging

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Headache News and Research

Latest Headache News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in